Garza-Morales S, Briceño-González E, Ceja-Moreno H, Ruiz-Sandoval JL, Góngora-Rivera F, Rodríguez-Leyva I, Alonso-Rivera CG

Language: Spanish
References: 24
Page: 215-224
PDF size: 317.47 Kb.

ABSTRACT

Background: Extended-release vinpocetine is effective to control focal onset epileptic seizures with a low rate of adverse events. A clinical study was performed to evaluate the efficacy and tolerability of vinpocetine as an adjuvant treatment in patients with this condition. Methods: A double-blind clinical study of parallel groups was conducted, in which 87 patients with a diagnosis of focal epilepsy treated with one to three antiepileptic drugs were recruited. Patients were randomized to receive vinpocetine (n = 41) or placebo (n = 46) adjuvant to their treatment. Patients entered the baseline phase (4 weeks), the titration phase (4 weeks) and the evaluation phase (8 weeks), maintaining stable doses of vinpocetine and their respective antiepileptic drug treatment. Results: Vinpocetine was more effective than placebo in reducing seizures at the end of the evaluation phase (p ‹ 0.0001). Sixty-nine percent of the vinpocetine-treated patients had a 50% reduction in seizures compared to 13% of placebo-treated patients. No significant differences in the presence of adverse effects in patients treated with vinpocetine compared to those treated with placebo were observed. The most frequent adverse events observed with vinpocetine were headache (7.9%) and diplopia (5.2%). Conclusions: As an adjuvant treatment, vinpocetine (2 mg/kg/day) effectively reduced the frequency of epileptic seizures and proved to be well tolerated. Vinpocetine has a wide safety profile and well-known adverse events, which are transient and with no sequelae.

REFERENCES

1. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475-82.

2. Epilepsiamexico.gob.mx [Internet]. México: PPE. Programa Prioritario de Epilepsia; 2011. Disponible en: http://www.epilepsiamexico.gob.mx/index. html.

3. Scheffer IE, French J, Hirsch E, Jain S, Mathern GW, Moshe SL, et al. Classification of the epilepsies: New concepts for discussion and debate— Special report of the ILAE Classification Task Force of the Commission for Classification and Terminology. Epilepsia Open. 2016;1:37-44.

4. Lingamaneni R, Hemmings HCJr. Differential interaction of anaesthetics and antiepileptic drugs with neuronal Na+ channels, Ca2+ channels, and GABA(A) receptors. Br J Anaesth. 2003;90:199-211.

5. Ambrosio AF, Silva AP, Malva JO, Soares-da-Silva P, Carvalho AP, Carvalho CM. Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem Pharmacol. 2001;61:1271-5.

6. Vermeulen J, Aldenkamp AP. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res. 1995;22:65-95.

7. Gates JR. Side effect profiles and behavioral consequences of antiepileptic medications. Epilepsy Behav. 2000;1:153-9.

8. Brunbech L, Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents. Drugs. 2002;62:593-604.

9. Schmidt D. The clinical impact of new antiepileptic drugs after a decade of use in epilepsy. Epilepsy Res. 2002;50:21-32.

10. Tatum WO 4th, Benbadis SR, Vale FL. The neurosurgical treatment of epilepsy. Arch Fam Med. 2000;9:1142-7.

11. Erdo SA, Molnár P, Lakcis V, Bence JZ, Tömösközi Z. Vincamine and vincanol are potent blockers of voltage-gated Na+ channels. Eur J Pharmacol. 1996;314:69-73.

12. Nekrassov V, Sitges M. Vinpocetine inhibits the epileptic cortical activity and auditory alterations induced by pentylenetetrazole in the guinea pig in vivo. Epilepsy Res. 2004;60:63-71.

13. Dutov AA, Tolpyshev BA, Petrov AP, Gladun VN. [Use of cavinton in epilepsy]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1986;86:850-5.

14. Dutov AA, Gal’tvanitsa GA, Volkova VA, Sukhanova ON, Lavrishcheva TG, Petrov AP. [Cavinton in the prevention of the convulsive syndrome in children after birth injury]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1991;91:21-2.

15. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika. 1965;52:591-611.

16. Wilcoxon F. Individual comparisons by ranking methods. Biometr Bull. 1945;1:80-3.

17. Yu K, Moyeed RA. Bayesian quantile regression. Stat Probabil Lett. 2001;54:437-47.

18. Bottai M, Cai B, McKeown RE. Logistic quantile regression for bounded outcomes. Stat Med. 2010;29:309-17.

19. Fisher RA. The logic of inductive inference. J R Stat Soc. 1935;98:39-82.

20. Gelman A, Jakulin A, Pittau MG, Yu-Sung Su. A weakly informative default prior distribution for logistic and other regression models. Ann Appl Stat. 2008;2:1360-83.

21. Gelman A, Hill J. Data Analysis Using Regression and Multilevel/Hierarchical Models. New York: Cambridge University Press; 2007.

22. Galván E, Sitges M. Characterization of the participation of sodium channels on the rise in Na+ induced by 4-aminopyridine (4-AP) in synaptosomes. Neurochem Res. 2004;29:347-55.

23. Sitges M, Galván E, Nekrassov V. Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. Neurochem Int. 2005;46:533-40.

24. Sitges M, Chiu LM, Guarneros A, Nekrassov V. Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na+ channel-mediated release of [3H]glutamate in hippocampal nerve endings. Neuropharmacology. 2007;52:598-605.